Envista (NVST) 7th Annual Evercore ISI HealthCONx Conference summary
Event summary combining transcript, slides, and related documents.
7th Annual Evercore ISI HealthCONx Conference summary
12 Jan, 2026Market trends and patient traffic
Dental market described as slow but stable, with steady patient traffic and no significant changes in general procedures.
Higher-ticket procedures like implants and advanced orthodontics have slowed, while basic procedures remain unchanged.
Optimism exists for future improvement tied to lower interest rates and rising consumer confidence, though not yet reflected in financials.
Impact of interest rates and purchasing behavior
Lower interest rates are expected to benefit dental market growth, especially for equipment purchases and site expansions.
Financing is a key factor for both clinicians and patients, particularly for expensive procedures.
Inventory normalization and channel dynamics
North American distributor inventory levels have normalized from pandemic highs, now at about half the previous levels.
Inventory drawdown has impacted orders and financials, with Q4 levels expected to remain stable.
China faces higher inventory volatility due to macroeconomic factors and VBP (volume-based procurement) effects, with stabilization efforts ongoing.
Latest events from Envista
- Double-digit core growth and margin gains in 2025 set the stage for continued momentum in 2026.NVST
Q4 20256 Feb 2026 - Targets 2%-4% core growth and 7%-10% EPS growth, driven by innovation and operational discipline.NVST
CMD 20253 Feb 2026 - Q2 loss of $1.15B on impairments; sales, margins fell, but cash flow and Q4 outlook improved.NVST
Q2 20242 Feb 2026 - Q3 2024 sales fell 5.3%, net income dropped, but full-year guidance was reaffirmed.NVST
Q3 202417 Jan 2026 - Dental market growth, innovation, and operational execution drive double-digit financial gains.NVST
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Strategic investments and stable market trends position the business for renewed growth.NVST
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q1 2025 core sales rose 0.2% with stable guidance and effective risk mitigation.NVST
Q1 202523 Dec 2025 - Q4 core sales rose 2% with strong cash flow and a $250M buyback, despite a net loss.NVST
Q4 202419 Dec 2025 - Stable dental market growth, innovation, and operational gains drive strong performance and outlook.NVST
Evercore ISI 8th Annual HealthCONx Conference3 Dec 2025